Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | HK1 | P19367 | 1/20 | 0.32 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2912855 | 0.80 | CYP2C19 (0.35) | CYP2C19HK1HKDC1SLC29A1CYP1A2 | |
| SCHEMBL3375933 | 0.79 | POLB (0.49) | — | |
| SCHEMBL2914175 | 0.76 | CYP2C19 (0.34) | CYP2C19HK1HKDC1SLC29A1CYP1A2 | |
| SCHEMBL2910504 | 0.75 | CYP2C19 (0.37) | CYP2C19HK1HKDC1SLC29A1CYP1A2 | |
| SCHEMBL2908457 | 0.74 | CYP2C19 (0.37) | CYP2C19HK1HKDC1SLC29A1CYP1A2 | |
| SCHEMBL5669549 | 0.73 | CYP2C19 (0.35) | CYP2C19HK1HKDC1SLC29A1CYP1A2 | |
| SCHEMBL5669560 | 0.73 | CYP2C19 (0.35) | CYP2C19HK1HKDC1SLC29A1CYP1A2 | |
| SCHEMBL3290187 | 0.73 | HSP90AA1 (0.33) | CYP2C19HK1HKDC1CYP1A2PNP | |
| SCHEMBL2991768 | 0.73 | ADORA2A (0.34) | CYP2C19HK1HKDC1SLC29A1CYP1A2 | |
| SCHEMBL2991772 | 0.72 | ADORA2A (0.35) | CYP2C19HK1HKDC1SLC29A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723319-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2010-05-25 | — | — | US | disclosed |
| US-7605147-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2009-10-20 | — | — | US | disclosed |
| US-7157448-B2 | Acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2007-01-02 | — | — | US | disclosed |
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | CHO DONG-GYU | 2006-12-28 | — | — | US | disclosed |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | LG LIFE SCIENCES LTD. (KR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293284-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | CYP2C19 681/4885HK1 1106/4885HKDC1 1842/4885 |
| US-20040063668-A1 | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same | PNP, ITPA, MTAP | CYP2C19 681/4885HK1 1106/4885HKDC1 1842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.